Janux Therapeutics, Inc.

JANX Nasdaq SEC CIK 1817713
Follow Janux Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $9.3M −7.1% vs same quarter last year
Net income −$21.6M +11.3% vs same quarter last year
EPS, diluted −$0.34 +12.8% vs same quarter last year
Operating cash flow −$25.2M −95.9% vs same quarter last year
Revenue by quarter
$0
$0
$0
$10M
$0
$3.7M
$10.3M
$9.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$10M−$113.6M
FY24$10.6M−$69M
FY23$8.1M−$58.3M
FY22$8.6M−$63.1M
FY21$3.6M−$32.7M
FY20$0−$6.8M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1576.7%−1136.2%
FY24−933.6%−651.6%
FY23−902.9%−721.2%
FY22−779%−732.2%
FY21−905.4%−898.3%
FY20--
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$83.3M
FY24−$44.2M
FY23−$52.4M
FY22−$49.4M
FY21−$18.5M
FY20−$4.4M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Janux Therapeutics
  • Healthcare median
−1500%−1000%−500%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearJanux TherapeuticsHealthcare median
FY25−1136.2%−30.6%
FY24−651.6%−47%
FY23−721.2%−58%
FY22−732.2%−80.4%
FY21−898.3%−71.8%
FY20-−62.2%
FY19-−46.2%